戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 everal other disorders can mimic polymyalgia rheumatica.
2 pains and stiffness diagnosed as polymyalgia rheumatica.
3 ts with glucocorticoid-dependent polymyalgia rheumatica.
4 eutic innovations to people with polymyalgia rheumatica.
5  active glucocorticoid-dependent polymyalgia rheumatica.
6 ions, and malignancies can mimic polymyalgia rheumatica.
7 cally useful in the treatment of polymyalgia rheumatica.
8 e phase reactants are typical of polymyalgia rheumatica.
9 heralded by symptoms of isolated polymyalgia rheumatica (1 case versus 5 in the placebo group; P = 0.
10  million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0
11 ere persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive
12 fy the pathological substrate of polymyalgia rheumatica and it is increasingly used to support clinic
13 s; both shared associations with polymyalgia rheumatica and rheumatoid arthritis.
14 nical features characteristic of polymyalgia rheumatica and/or giant cell arteritis (GCA).
15 l [CI] 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.82 for syste
16  Participants were patients with polymyalgia rheumatica and/or giant cell arteritis who were investig
17  are headache, jaw claudication, polymyalgia rheumatica, and visual symptoms.
18 trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017
19 rd review: rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis, and a
20 olution of signs and symptoms of polymyalgia rheumatica by week 12 and sustained normalization of the
21       Among patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, comp
22                         Although polymyalgia rheumatica does not clearly impair survival or organ fun
23 se in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering.
24  provides a clinical overview of polymyalgia rheumatica, focusing on risk factors, diagnosis, treatme
25  More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocortic
26 als with prior diagnoses of GCA, polymyalgia rheumatica, HIV, or transplant status were excluded.
27                                  Polymyalgia rheumatica is a chronic, inflammatory disorder of unknow
28                                  Polymyalgia rheumatica is an inflammatory disease producing pain and
29                                  Polymyalgia rheumatica is an inflammatory disease that affects the s
30 with giant cell arteritis and/or polymyalgia rheumatica (n = 25,581), inflammatory bowel disease (n =
31 1-1.2), P=9.8 x 10(-11)) and for polymyalgia rheumatica near C6orf10 at rs6910071 (OR=1.5 (95% CI: 1.
32                                  Polymyalgia rheumatica occurred with similar frequency in both patie
33 ional study of 267 patients with polymyalgia rheumatica or giant cell arteritis found a GIAI prevalen
34                                  Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are rela
35   Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditions characte
36                                  Polymyalgia rheumatica (PMR) has an abrupt onset of inflammatory sym
37 or joint disease localization in polymyalgia rheumatica (PMR) is poorly understood.
38                                  Polymyalgia rheumatica (PMR) is the second most common inflammatory
39        To evaluate the impact of polymyalgia rheumatica (PMR) on clinical outcomes and quality of lif
40       Imaging studies in GCA and polymyalgia rheumatica (PMR) suggest that vasculitis can affect mult
41     GCA frequently overlaps with polymyalgia rheumatica (PMR), a rheumatic inflammatory condition aff
42                 In patients with polymyalgia rheumatica (PMR), a subclinical variant of GCA, adventit
43 bnormalities, fever, concomitant polymyalgia rheumatica (PMR), and histologic evidence of giant cell
44  are headache, jaw claudication, polymyalgia rheumatica (PMR), and visual symptoms, but 40% of patien
45 thematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant cell arteritis, ankylosing spond
46 logy classification criteria for polymyalgia rheumatica (PMR).
47 scular diseases in patients with polymyalgia rheumatica (PMR).
48 -interleukin 6, in patients with polymyalgia rheumatica that is refractory to glucocorticoids require
49                 One patient with polymyalgia rheumatica who developed the inhibitor while receiving p
50 osing vasculitis; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammation, and sub